Elite Pharmaceuticals annual gross margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Elite Pharmaceuticals Gross Margin Growth & History (ELTP)
Elite Pharmaceuticals's gross margin was 50.40% for fiscal 2026.
View full Elite Pharmaceuticals company overviewElite Pharmaceuticals annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-03-31 | 50.40% | +2.70 pp |
| 2025 | 2025-03-31 | 47.70% | +1.15 pp |
| 2024 | 2024-03-31 | 46.55% | −2.04 pp |
| 2023 | 2023-03-31 | 48.58% | +2.72 pp |
| 2022 | 2022-03-31 | 45.86% | −0.90 pp |
| 2021 | 2021-03-31 | 46.76% | +2.42 pp |
| 2020 | 2020-03-31 | 44.34% | +6.45 pp |
| 2019 | 2019-03-31 | 37.89% | −15.04 pp |
| 2018 | 2018-03-31 | 52.93% | +14.13 pp |
| 2017 | 2017-03-31 | 38.80% | −25.32 pp |
| 2016 | 2016-03-31 | 64.12% | +24.21 pp |
| 2015 | 2015-03-31 | 39.91% | +10.24 pp |
| 2014 | 2014-03-31 | 29.67% | −2.31 pp |
| 2013 | 2013-03-31 | 31.98% | −26.21 pp |
| 2012 | 2012-03-31 | 58.18% | +20.89 pp |
| 2011 | 2011-03-31 | 37.29% | — |
Elite Pharmaceuticals quarterly gross margin
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q1 2027 | 2026-06-30 | 41.75% | −25.96 pp |
| Q4 2026 | 2026-03-31 | 50.98% | −3.08 pp |
| Q3 2026 | 2025-12-31 | 41.01% | −1.60 pp |
| Q2 2026 | 2025-09-30 | 38.75% | −4.67 pp |
| Q1 2026 | 2025-06-30 | 67.71% | +22.64 pp |
| Q4 2025 | 2025-03-31 | 54.05% | +8.82 pp |
| Q3 2025 | 2024-12-31 | 42.60% | −2.71 pp |
| Q2 2025 | 2024-09-30 | 43.42% | −2.12 pp |
| Q1 2025 | 2024-06-30 | 45.07% | −7.83 pp |
| Q4 2024 | 2024-03-31 | 45.23% | +0.67 pp |
| Q3 2024 | 2023-12-31 | 45.31% | −7.87 pp |
| Q2 2024 | 2023-09-30 | 45.54% | +1.00 pp |
| Q1 2024 | 2023-06-30 | 52.90% | +0.80 pp |
| Q4 2023 | 2023-03-31 | 44.56% | −0.49 pp |
| Q3 2023 | 2022-12-31 | 53.18% | +8.41 pp |
| Q2 2023 | 2022-09-30 | 44.54% | +0.52 pp |
| Q1 2023 | 2022-06-30 | 52.10% | +1.75 pp |
| Q4 2022 | 2022-03-31 | 45.05% | +2.60 pp |
| Q3 2022 | 2021-12-31 | 44.77% | −11.52 pp |
| Q2 2022 | 2021-09-30 | 44.03% | −4.91 pp |
| Q1 2022 | 2021-06-30 | 50.36% | +10.87 pp |
| Q4 2021 | 2021-03-31 | 42.45% | −7.28 pp |
| Q3 2021 | 2020-12-31 | 56.29% | −0.92 pp |
| Q2 2021 | 2020-09-30 | 48.94% | +20.27 pp |
| Q1 2021 | 2020-06-30 | 39.48% | +0.81 pp |
| Q4 2020 | 2020-03-31 | 49.73% | +10.07 pp |
| Q3 2020 | 2019-12-31 | 57.20% | +22.95 pp |
| Q2 2020 | 2019-09-30 | 28.67% | −31.53 pp |
| Q1 2020 | 2019-06-30 | 38.67% | +11.39 pp |
| Q4 2019 | 2019-03-31 | 39.66% | −31.48 pp |
| Q3 2019 | 2018-12-31 | 34.26% | −9.75 pp |
| Q2 2019 | 2018-09-30 | 60.20% | −1.93 pp |
| Q1 2019 | 2018-06-30 | 27.28% | −13.11 pp |
| Q4 2018 | 2018-03-31 | 71.13% | −16.13 pp |
| Q3 2018 | 2017-12-31 | 44.00% | +18.09 pp |
| Q2 2018 | 2017-09-30 | 62.12% | +31.04 pp |
| Q1 2018 | 2017-06-30 | 40.39% | +6.06 pp |
| Q4 2017 | 2017-03-31 | 87.26% | +7.20 pp |
| Q3 2017 | 2016-12-31 | 25.91% | −35.98 pp |
| Q2 2017 | 2016-09-30 | 31.09% | −20.90 pp |
| Q1 2017 | 2016-06-30 | 34.33% | −10.33 pp |
| Q4 2016 | 2016-03-31 | 80.06% | +53.23 pp |
| Q3 2016 | 2015-12-31 | 61.90% | +13.25 pp |
| Q2 2016 | 2015-09-30 | 51.99% | +6.20 pp |
| Q1 2016 | 2015-06-30 | 44.66% | +7.40 pp |
| Q4 2015 | 2015-03-31 | 26.82% | +28.57 pp |
| Q3 2015 | 2014-12-31 | 48.64% | +7.36 pp |
| Q2 2015 | 2014-09-30 | 45.78% | −0.98 pp |
| Q1 2015 | 2014-06-30 | 37.26% | +17.46 pp |
| Q4 2014 | 2014-03-31 | −1.75% | −28.57 pp |
| Q3 2014 | 2013-12-31 | 41.29% | −18.75 pp |
| Q2 2014 | 2013-09-30 | 46.76% | +22.35 pp |
| Q1 2014 | 2013-06-30 | 19.81% | −1.66 pp |
| Q4 2013 | 2013-03-31 | 26.82% | −18.51 pp |
| Q3 2013 | 2012-12-31 | 60.04% | −9.25 pp |
| Q2 2013 | 2012-09-30 | 24.41% | −47.75 pp |
| Q1 2013 | 2012-06-30 | 21.47% | −35.57 pp |
| Q4 2012 | 2012-03-31 | 45.33% | +32.41 pp |
| Q3 2012 | 2011-12-31 | 69.29% | +21.61 pp |
| Q2 2012 | 2011-09-30 | 72.16% | +29.02 pp |
| Q1 2012 | 2011-06-30 | 57.03% | +6.52 pp |
| Q4 2011 | 2011-03-31 | 12.93% | — |
| Q3 2011 | 2010-12-31 | 47.69% | — |
| Q2 2011 | 2010-09-30 | 43.13% | — |
| Q1 2011 | 2010-06-30 | 50.52% | — |
Elite Pharmaceuticals gross margin trends
Over the last five fiscal years, Elite Pharmaceuticals's gross margin increased from 46.76% to 50.40%, a change of +3.64 percentage points. The latest reported quarter, Q1 2027, shows 41.75%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Elite Pharmaceuticals source filings ↗